Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Asaf Zviran, Rafael Schulman, Minita Shah, et al.
Nature Medicine (2020) Vol. 26, Iss. 7, pp. 1114-1124
Open Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

Liquid biopsy enters the clinic — implementation issues and future challenges
Michail Ignatiadis, George W. Sledge, Stefanie S. Jeffrey
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 5, pp. 297-312
Closed Access | Times Cited: 822
From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment
Kyle Swanson, Eric Q. Wu, Angela Zhang, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1772-1791
Closed Access | Times Cited: 212
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
Frederick Lang, Ming-Chin Lee, John R. Teijaro, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 8, pp. 507-514
Open Access | Times Cited: 211
Mutational signatures: emerging concepts, caveats and clinical applications
Ching Chiek Koh, Andrea Degasperi, Xueqing Zou, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 619-637
Closed Access | Times Cited: 198
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
Davina Gale, Katrin Heider, Andrea Ruiz-Valdepeñas, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 500-510
Open Access | Times Cited: 190
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Everett J. Moding, Barzin Y. Nabet, Ash A. Alizadeh, et al.
Cancer Discovery (2021) Vol. 11, Iss. 12, pp. 2968-2986
Open Access | Times Cited: 182
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 168
Big data in basic and translational cancer research
Peng Jiang, Sanju Sinha, Kenneth Aldape, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 11, pp. 625-639
Open Access | Times Cited: 148
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M. Stütz, Didier Surdez, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 139
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1690-1701
Open Access | Times Cited: 136
Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent
Bruna Pellini, Aadel A. Chaudhuri
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 567-575
Open Access | Times Cited: 127
Inferring gene expression from cell-free DNA fragmentation profiles
Mohammad Shahrokh Esfahani, Emily G. Hamilton, Mahya Mehrmohamadi, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 4, pp. 585-597
Open Access | Times Cited: 124
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
Biagio Ricciuti, Greg Jones, Mariano Severgnini, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001504-e001504
Open Access | Times Cited: 103
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges
Enrique Sanz‐García, Eric Y. Stutheit-Zhao, Scott V. Bratman, et al.
Science Advances (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 103
A clinician’s handbook for using ctDNA throughout the patient journey
Samantha O. Hasenleithner, Michael R. Speicher
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 80
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future
Dilara Akhoundova, Mark A. Rubin
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 920-938
Open Access | Times Cited: 76
Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing
Efrat Katsman, Shari Orlanski, Filippo Martignano, et al.
Genome biology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 64
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Carmen Martin-Alonso, Shervin Tabrizi, Kan Xiong, et al.
Science (2024) Vol. 383, Iss. 6680
Open Access | Times Cited: 58
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 57
Bridging biological cfDNA features and machine learning approaches
Tina Moser, Stefan Kühberger, Isaac Lazzeri, et al.
Trends in Genetics (2023) Vol. 39, Iss. 4, pp. 285-307
Open Access | Times Cited: 56
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Mingyang Li, Lei Li, Jianyi Zheng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 45
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 498-512
Closed Access | Times Cited: 31
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 23
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
Adam J. Widman, Minita Shah, Amanda Frydendahl, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1655-1666
Open Access | Times Cited: 15
Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy
Shengnan Jin, Dewen Zhu, Fanggui Shao, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 5
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top